AZ field tests COFLUX tool

AstraZeneca is the first pharma company to undertake field tests of a new process monitoring tool incorporating the novel concept of Constant Flux (COFLUX) calorimetry. The tests were commissioned to assess the suitability of COFLUX as a scalable monitoring tool in AZ's primary manufacturing processes.

COFLUX is a patented technology developed by UK-based Ashe Morris that permits stirred tank reactors of virtually any size or type to be operated as precision calorimeters. It is said to offer a simple and versatile solution for on-line monitoring of chemical, physical and biological processes.

A series of more than 35 tests were conducted at AZ's Macclesfield site to evaluate the accuracy, sensitivity and usability of the technology. The system used in the trials was a 10-litre Constant Flux reaction calorimeter with a Hastelloy body. Power and enthalpy data were monitored in real time and displayed on a Eurotherm 5180v data management unit (21 CFR part 11 compliant).

The outcome of the tests was positive, with COFLUX meeting AZ's pre-determined performance criteria. 'The positive outcome of the AstraZeneca tests further reinforces the unique capabilities of COFLUX,' said David Morris, a co-founder of Ashe Morris.

'It allows process operators to accurately monitor chemical synthesis reactions, biological processes and crystallisations. This could improve process economics by enhancing yield, product quality and capital utilisation.'

Ashe Morris's licensee in the lab market, Syrris & Radleys, will be launching standardised lab-scale COFLUX calorimeters as part of its LARA range in the summer of 2005. Ashe Morris's licensee in the pilot and industrial markets, PSL, is developing a range of COFLUX batch reactors from five litres through to 10,000 litres.